Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosgonimeton - Athira Pharma

Next Previous
Drug Profile

Fosgonimeton - Athira Pharma

Alternative Names: ATH-1017; NDX-1017

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator M3 Biotechnology
  • Developer Athira Pharma
  • Class Amides; Amino acids; Antidementias; Antiparkinsonians; Benzyl compounds; Phosphates; Small molecules
  • Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alzheimer's disease; Dementia; Parkinson's disease

Most Recent Events

  • 09 May 2025 Fosgonimeton - Athira Pharma is available for licensing as of 09 May 2025. https://www.athira.com/pipeline/#1640377031-2-83
  • 01 Apr 2025 Athira Pharma terminates the phase II/III open-label extension trial for Alzheimer's Disease in USA (SC, Injection), as the phase II/III LIFT-AD trial did not meet its primary endpoint (NCT04886063)
  • 07 Nov 2024 Suspended - Phase-I for Alzheimer's disease in France (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top